When and how to treat pulmonary non-tuberculous mycobacterial diseases

Respirology

Volumn 14, Issue 1, 2009, Pages 12-26

  Thomson, Rachel M ^a,b,c   Yew, Wing Wai ^d  

^a Specialised Health Services   (Australia)

^b Specialised Health Services   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Anti mycobacterial therapeutics; Bronchiectasis; Lung diseases; Mycobacteria; Non tuberculous

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSPORIN; DOXYCYCLINE; EFAVIRENZ; ETHAMBUTOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPENEM; ISONIAZID; ITRACONAZOLE; KANAMYCIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; NEVIRAPINE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; TERFENADINE; TOBRAMYCIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANTIBIOTIC SENSITIVITY; ANXIETY; APLASTIC ANEMIA; ARTHRALGIA; ARTHROPATHY; ATAXIA; BRONCHIECTASIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EYE TOXICITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEARING IMPAIRMENT; HEARING LOSS; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERPIGMENTATION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INSOMNIA; INTESTINE OBSTRUCTION; KIDNEY FAILURE; KIDNEY INJURY; LEUKOPENIA; LIVER DYSFUNCTION; LUNG INFECTION; LUNG RESECTION; LUNG TUBERCULOSIS; MENTAL DISEASE; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MALMOENSE; MYCOBACTERIUM SZULGAI; MYCOBACTERIUM XENOPEI; NAUSEA; NEPHROTOXICITY; OPTIC NERVE DISEASE; OPTIC NEURITIS; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIZATION; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RASH; RETINOPATHY; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SHOCK; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; TASTE; TENDINITIS; TENDON RUPTURE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THRUSH; TINNITUS; TREMOR; UVEITIS; VERTIGO; VESTIBULAR DISORDER;

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; COMBINED MODALITY THERAPY; HUMANS; LUNG DISEASES; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM KANSASII; PRACTICE GUIDELINES AS TOPIC;

EID: 58149139063     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2008.01408.x     Document Type: Review

References (117)

1. Falkinham J III. Nontuberculous mycobacteria in the environment. Clin. Chest Med. 2002 23 : 529 52.
2. Marras T, Daley C. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin. Chest Med. 2002 23 : 553 67.
3. Henry MT, Inamdar L, O'Riordain D, Schweiger M, Watson JP. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur. Respir. J. 2004 23 : 741 6.
4. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007 62 : 661 6.
5. Fujita J, Ohtsuki Y, Suemitsu I, Shigeto E, Yamadori I et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium-intracellulare complex disease. Eur. Respir. J. 1999 13 : 535 40.
6. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am. J. Respir. Crit. Care Med. 2007 176 : 306 13.
7. Haverkort F, Australian Mycobacterium Reference Laboratory Network. National atypical mycobacteria survey, 2000. Commun. Dis. Intell. 2003 27 : 180 9.
8. Thomsen V, Andersen A, Miorner H. Incidence and clinical significance of non-tuberculous mycobacteria isolated from clinical specimens during a 2 year nationwide survey. Scand. J. Infect. Dis. 2002 34 : 648 53.
9. Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VØ, Curcio M et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int. J. Tuberc. Lung Dis. 2004 8 : 1186 93.
10. Maliwan N, Zvetina J. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad. Med. J. 2005 81 : 530 3.
11. Costrini A, Mahler D, Gross W, Hawkins J, Yesner R et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am. Rev. Respir. Dis. 1981 123 : 104 9.
12. The Research Committee of the British Thoracic Society. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur. Respir. J. 2003 21 : 478 82.
13. Griffith D, Girard W, Wallace R Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am. Rev. Respir. Dis. 1993 147 : 1217 18.
14. Iseman M, Buschman D, Ackerson L. Pectus excavatum and scoliosis: thoracic abnormalities associated with pulmonary disease caused by Mycobacterium avium complex. Am. Rev. Respir. Dis. 1991 144 : 914 16.
15. Kwon Y, Koh W, Kwon OJ, Lee N, Han J et al. Mycobacterium abscessus pulmonary infection presenting as a solitary pulmonary nodule. Intern. Med. 2006 45 : 169 71.
16. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y et al. Four cases of pulmonary Mycobacterium avium intracellulare complex presenting as a solitary pulmonary nodule and a review of other cases in Japan. Respirology 2006 11 : 317 21.
17. Gribetz A, Damsker B, Bottone E, Kirschner P, Teirstein A. Solitary pulmonary nodules due to nontuberculous mycobacterial infection. Am. J. Med. 1981 70 : 39 43.
18. Embil J, Warren P, Yakrus M, Stark R, Corne S et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? Chest 1997 111 : 813.
19. Khoor A, Leslie K, Tazelaar H, Helmers R, Colby T. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am. J. Clin. Pathol. 2001 115 : 755 62.
20. Bernstein D, Lummus Z, Santilli G, Siskorsky J, Berstein I. Machine operator's lung, a hypersensitivity pneumonitis disorder associated with exposure to metalworking fluid aerosols. Chest 1995 108 : 636 41.
21. Centers for Disease Control and Prevention. Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria - Ohio, 2001. MMWR 2002 51 : 349 52.
22. Olivier KN, Weber DJ, Wallace RJ Jr., Faiz AR, Lee J-H et al. Nontuberculous mycobacteria: I: multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003 167 : 828 34.
23. Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007 131 : 1166 72.
24. Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur. Respir. J. 2006 28 : 352 7.
25. Jeong Y, Lee K, Koh W, Han J, Kim T et al. Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin section CT and histopathologic findings. Radiology 2004 231 : 880 6.
26. Koh W-J, Lee KS, Kwon OJ, Jeong YJ, Kwak S-H et al. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology 2005 235 : 282 8.
27. Reich J, Johnson R. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992 101 : 1605 9.
28. Obayashi Y, Fujii N, Suemitsu I, Kamei T, Takahara MN et al. Successive follow-up of chest computed tomography in patients with Mycobacterium avium-intracellulare complex. Respir. Med. 1999 93 : 11 15.
29. Tanaka D, Niwatsukino H, Oyama T, Nakajo M. Progressing features of atypical mycobacterial infection in the lung on conventional and high resolution CT (HRCT) images. Radiat. Med. 2001 19 : 237 45.
30. Hartman TE, Jensen E, Tazelaar HD, Hanak V, Ryu JH. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium-intracellulare inhalation: 'hot tub lung'. Am. J. Roentgenol. 2007 188 : 1050 3.
31. Runyon E. Typical mycobacteria: their classification. Am. Rev. Respir. Dis. 1965 91 : 288 9.
32. Leitritz L, Schubert S, Bucherl B, Masch A, Heesemann J et al. Evaluation of BACTEC MGIT 960 and BACTEC 460TB systems for recovery of mycobacteria from clinical specimens of a university hospital with low incidence of tuberculosis. J. Clin. Microbiol. 2001 39 : 3764 7.
33. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 1997 156 : S1 25.
34. Wilton S, Cousins D. Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube. PCR Methods Appl. 1992 4 : 269 73.
35. Cloud JL, Neal H, Rosenberry R, Turenne CY, Jama M et al. Identification of Mycobacterium spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries. J. Clin. Microbiol. 2002 40 : 400 6.
36. Cloud JL, Hoggan K, Belousov E, Cohen S, Brown-Elliott BA et al. Use of the MGB eclipse system and SmartCycler PCR for differentiation of Mycobacterium chelonae and M. abscessus. J. Clin. Microbiol. 2005 43 : 4205 7.
37. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An Official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007 175 : 367 416.
38. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob. Agents Chemother. 1996 40 : 1759 67.
39. Banks J, Jenkins P. Combined versus single antituberculous drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987 42 : 838 42.
40. Horsburgh C Jr., Mason U 3rd., Heifets L. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am. Rev. Respir. Dis. 1987 135 : 418 21.
41. Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am. Rev. Respir. Dis. 1988 137 : 144 8.
42. The Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium-intracellulare, M. malmoense and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001 56 : 167 72.
43. Heifets L. Synergistic effects of rifampicin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am. Rev. Respir. Dis. 1982 125 : 43 8.
44. Wallace RJ, Zhang Y, Brown BA, Dawson D, Murphy DT et al. Polyclonal Mycobacterium avium Complex infections in patients with nodular bronchiectasis. Am. J. Respir. Crit. Care Med. 1998 158 : 1235 44.
45. Semret M, Turenne CY, de Haas P, Collins DM, Behr MA. Differentiating host-associated variants of Mycobacterium avium by PCR for detection of large sequence polymorphisms. J. Clin. Microbiol. 2006 44 : 881 7.
46. Huebner RE, Schein MF, Cauthen GM, Geiter LJ, Selin MJ et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am. Rev. Respir Dis. 1992 145 : 1160 6.
47. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N et al. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin. Infect. Dis. 2006 43 : 1540 6.
48. Detjen AK, Keil T, Roll S, Hauer B, Mauch H et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin. Infect. Dis. 2007 45 (3 322 8.
49. Tobin-D'Angelo MJ, Blass MA, del Rio C, Halvosa JS, Blumberg HM et al. Hospital water as a source of Mycobacterium avium complex isolates in respiratory specimens. J. Infect. Dis. 2004 189 : 98 104.
50. Collins C, Yates M. Infection and colonisation by Mycobacterium kansasii and Mycobacterium xenopi: aerosols as a possible source? J. Infect. 1984 8 : 178 9.
51. Wolinsky E. When is an infection disease? Rev. Infect. Dis. 1981 3 : 1025 7.
52. Rossman M. Colonization with Mycobacterium avium complex - an outdated concept. Eur. Respir. J. 1999 13 : 479.
53. Corbett E, Blumberg L, Churchyard G, Moloi N, Mallory K et al. Nontuberculous mycobacteria. Defining disease in a prospective cohort of South African miners. Am. J. Resp. Crit. Care Med. 1999 160 : 15 21.
54. Hunter A, Campbell I, Jenkins P, Smith A. Treatment of pulmonary infections caused by the Mycobacterium avium-intracellulare complex. Thorax 1981 36 : 326 9.
55. Yeager J, Raleigh J. Pulmonary disease due to M. intracellulare. Am. Rev. Respir. Dis. 1973 108 : 547 52.
56. Prince D, Peterson D, Steiner R, Gottlieb J, Scott R et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N. Engl. J. Med. 1989 321 : 863.
57. Maekura R, Okuda Y, Hirotani A, Kitada S, Hiraga T et al. Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients. J. Clin. Microbiol. 2005 43 : 3150 8.
58. Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y et al. Mycobacterium avium complex disease: prognostic implication of high-resolution CT findings. Eur. Respir. J. 2008 32 : 147 52.
59. Kobashi YMT. Comparison of clinical features in patients with pulmonary Mycobacterium avium complex (MAC) disease treated before and after proposal for guidelines. J. Infect. Chemother. 2004 10 : 25 30.
60. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 1997 156 : S1 25.
61. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000 55 : 210 8.
62. The Japanese Society for Tuberculosis. Treatment of nontuberculous mycobacteriosis. Kekkaku 1998 73 : 599 605.
63. Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008 63 : 627 34.
64. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 2006 173 : 1283 9.
65. Dautzenburg B, Piperno D, Diot P, Chantal T-P, Chauvin J-P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995 107 : 1035 40.
66. Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. Am. J. Respir. Crit. Care Med. 1996 153 : 1766 72.
67. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 2006 174 : 928 34.
68. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 2001 32 : 1547 53.
69. Field S, Cowie R. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003 124 : 1482 6.
70. Griffith D, Brown-Elliott B, Girard W, Wallace R Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 1995 21 : 594 8.
71. Griffith D, Brown-Elliott B, Wallace Jr R. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regiments for pulmonary Mycoabcterium avium complex disease. Clin. Infect. Dis. 1996 23 : 1321 2.
72. Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob. Agents Chemother. 2007 51 : 4071 6.
73. Bermudez LE, Kofonoski P, Petrofsky M, Wu M, Inderfield CB et al. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J. Infect. Dis. 2003 187 : 1977 80.
74. Kobashi YMT, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir. Med. 2007 101 : 130 8.
75. Hanak V, Kalra S, Aksamit TR, Hartman TE, Tazelaar HD et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir. Med. 2006 100 : 610 15.
76. Ahn C, Lowell J, Ahn S, Ahn S, Hurst G. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am. Rev. Respir. Dis. 1983 128 : 1048 50.
77. The Research Committee of the British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax 1994 49 : 442 5.
78. Wallace R, Dunbar D, Brown B, Onyi G, Dunlap R et al. Rifampin-resistant Mycobacterium kansasii. Clin. Infect. Dis. 1994 18 : 736 43.
79. Griffith D, Brown-Elliott B, Wallace Jr R. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin. Infect. Dis. 2003 37 : 1178 82.
80. Alcaide F, Calatayud L, Santin M, Martin R. Comparative in vitro activities of linezolid, telithromicin, clarithromicin, levofloxacin, moxafloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob. Agents Chemother. 2004 48 : 4562 5.
81. Schroder K, Juhlin I. Mycobacterium malmoense sp nov. Int. J. Syst. Bacteriol. 1977 27 : 241 6.
82. Buchholz U, McNeil M, Keyes L, Good R. Mycobacterium malmoense infections in the United States; January 1993 through June 1995. Clin. Infect. Dis. 1998 27 : 551 8.
83. Nakayama S, Fujii T, Kadota J, Sawa H, Hamage S et al. Pulmonary mycobacteriosis caused by rifampicin-resistant Mycobacterium szulgai. Intern. Med. 2000 39 : 309 12.
84. Sanchez-Alarcos J, de Miguel-Diez J, Bonilla I, Sicilia J, Alvarez-Sala J. Pulmonary infection due to Mycobacterium szulgai. Respiration 2003 70 : 533 6.
85. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 1999 44 : 393 5.
86. Faress J, McKinney L, Semann M, Byrd R Jr., Mehta J et al. Mycobacterium xenopi pneumonia in the southeastern United States. South. Med. J. 2003 96 : 596 9.
87. Yew W, Kwan S, Wong P, Lee J. Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections. Tubercle 1992 71 : 131 3.
88. Yew W, Lau K, Tse W, Wong C. Imipenem in the treatment of lung infections due to Mycobacterium fortuitum and Mycobacterium chelonae. Clin. Infect. Dis. 1992 15 : 1046 7.
89. Wagner D, Young L. Nontuberculous mycobacterial infections: a clinical review. Infection 2004 32 : 257 70.
90. The Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV negative patients: five-year follow-up of patients receiving standardised treatment. Int. J. Tuberc. Lung Dis. 2002 6 : 628 34.
91. Brown BA, Wallace R Jr., Griffith D, Girard W. Clarithromycin induced hepatotoxicity. Clin. Infect. Dis. 1995 20 : 1073 4.
92. Brown BA, Griffith DE, Girard WM, Levin J, Wallace RJ. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin. Infect. Dis. 1997 24 : 958 64.
93. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 2005 172 : 250 3.
94. Wallace R Jr., Brown BA, Griffith D, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-intracellulare infection. J. Infect. Dis. 1995 171 : 747 50.
95. Kuper J, D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin. Pharmacokinet. 2000 39 : 203 14.
96. Thompson C, Harrison S, Ashley J, Day K, Smith D. Randomised crossover study of the flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002 57 : 446 8.
97. Daviskas E, Anderson S, Eberl S, Bautovich HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Resp. Crit. Care Med. 1999 159 : 1843 8.
98. Kellett F, Redfern J, Niven R. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med. 2005 99 : 27 31.
99. Nelson K, Griffith D, Brown-Elliott B, Wallace R Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann. Thorac. Surg. 1998 66 : 325 30.
100. Shiraishi Y, Nakajima Y, Takasuna K, Hanaoka T, Katsuragi N et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur. J. Cardiothorac. Surg. 2002 21 : 314 18.
101. Shiraishi Y, Fukushima K, Komatsu H, Kurashima A. Early pulmonary resection for localised Mycobacterium avium complex disease. Ann. Thorac. Surg. 1998 66 : 183 6.
102. Watanabe A, Hasegawa N, Ishizaka A, Asakura K, Tzumi Y et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann. Thorac. Surg. 2006 81 : 2026 30.
103. Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Pneumonectomy for nontuberculous mycobacterial infections. Ann. Thorac. Surg. 2004 78 : 399 403.
104. Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M et al. Serodiagnosis of Mycobacterium avium-Complex pulmonary disease using an enzyme immunoassay kit. Am. J. Respir. Crit. Care Med. 2008 177 : 793 7.
105. Kwon YS, Kim EJ, Lee S-H, Suh GY, Chung MP et al. Decreased cytokine production in patients with nontuberculous mycobacterial lung disease. Lung 2007 185 : 337 41.
106. Vankayalapati R, Wizel B, Samten B, Griffith D, Shams H et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J. Infect. Dis. 2001 183 : 478 84.
107. Greinert U, Schlaak M, Rusch-Gerdes S, Flad H, Ernst M. Low in vitro production of interferon-gamma and tumor necrosis factor alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria. J. Clin. Immunol. 2000 20 : 445 52.
108. Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 1995 152 : 1094 6.
109. Silva R, Pais T, Appelberg R. Evaluation of IL-12 in immunotherapy and vaccine design in experimental Mycobacterium avium infections. J. Immunol. 1998 161 : 5578 85.
110. Doherty T, Sher A IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J. Immunol. 1998 160 : 5428 35.
111. Brown-Elliot BA, Wallace R Jr., Blinkhorn R, Crist C, Mann L. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin. Infect. Dis. 2001 33 : 1433 44.
112. Yang S, Hsueh P, Lai H, Teng LJ, Huang LM et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob. Agents Chemother. 2003 47 : 1958 62.
113. Brown-Elliot B, Crist C, Mann L, Wilson R, Wallace R Jr. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob. Agents Chemother. 2003 47 : 1736 8.
114. Wallace R Jr., Brown-Elliot BA, Crist C, Mann L, Wilson R. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 2002 46 : 3164 7.
115. Huitric E, Verhasselt P, Andries K, Hoffner S. In vitro antimycobacterial spectrum of a diarylquinolone ATP synthase inhibitor. Antimicrob. Agents Chemother. 2007 51 : 4202 4.
116. Hickey A, Lu D, Ashley E, Stout J. Inhaled azithromycin therapy. J. Aerosol Med. 2006 19 : 54 60.
117. Davis K, Kao P, Jacobs S, Ruoss S. Aerosolized amikacin for treatment of Mycobacterium avium infections: an observational case series. BMC Pulm. Med. 2007 7 : 2.